Welcome to Flow Pharma Inc.

Page Loading...


Powerful Immunotherapy

in a Stable Dry Powder

Administration Options

  • Anti-Virus – inhalation & intramuscular

  • Anti-Cancer – intranodal & intramuscular

Rapid Development of Disease-Specific Therapy
High Volume Production Capability

The FlowVax Platform

A revolutionary targeted killer T-Cell immune system therapy (immunotherapy) platform validated by extensive animal testing in mice and macaques.

Medicines that precisely treat cancer and viral disease with minimal side effects.


A New Vaccine for COVID-19. Administered by inhaler.

Mutations Continue. Case-rates are unstable. New COVID-19 treatments and vaccines are needed. FLOVID-20 is designed to treat all known variants.

Under Development, FDA Approval Required

Vaccination by Inhalation

X-rays of COVID-19 exposed monkeys.

The left monkey was treated with FLOVID-20.

Under Development, FDA approval required.

Our Mission

Flow Pharma is dedicated to immunotherapy innovation.

Our exclusive technology and manufacturing expertise are poised to transform the treatment and prevention of cancer and viral disease.

Product Portfolio



An inhaled treatment to prevent COVID-19 disease in both virus-exposed and healthy patient populations.

FlowVax Ebola & Marburg

Ebola, Marburg

Marburg is a weaponized Ebola-like virus. By stimulating T-cells to target this virus, long-lasting infection prevention is attainable.

FlowVax BreastCA


A revolutionary T-cell biomedicine that provides new hope for those with treatment-resistant, triple-negative breast cancer.

FlowVax HPV

Cancer, HPV

A targeted T-cell immunotherapy for HPV-induced squamous cell carcinoma of the head, neck, and cervix.

Subscribe to Flow Pharma Updates